Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

INTRODUCTION: Proteinuria is one of the adverse events of atezolizumab plus bevacizumab combination therapy (Atezo + Bev) and can cause interruption in the use of Bev. However, the risk factors for proteinuria in patients with hepatocellular carcinoma (HCC) who are receiving Atezo + Bev have not yet...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Yuwa, Kawaoka, Tomokazu, Kosaka, Masanari, Shirane, Yuki, Johira, Yusuke, Miura, Ryoichi, Murakami, Serami, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Kosaka, Yumi, Uchikawa, Shinsuke, Kodama, Kenichiro, Fujino, Hatsue, Nakahara, Takashi, Ono, Atushi, Murakami, Eisuke, Yamauchi, Masami, Okamoto, Wataru, Takahashi, Shoichi, Imamura, Michio, Aikata, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433089/
https://www.ncbi.nlm.nih.gov/pubmed/37601981
http://dx.doi.org/10.1159/000528145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433089/
https://www.ncbi.nlm.nih.gov/pubmed/37601981
http://dx.doi.org/10.1159/000528145

Ejemplares similares